Group I (n = 113, 46.3%) | Group II (n = 14, 5.7%) | Group III (n = 38, 15.6%) | Group IV (n = 56, 23.0%) | Group V (n = 23, 9.4%) | Overall (n = 244, 100%) | Chi-square P value | |
---|---|---|---|---|---|---|---|
Dose of imipenem (%) | 0.51 | ||||||
<3 g/day | 19.5 | - | 10.5 | 9.0 | 17.3 | 14.3 | |
3 g/day | 62.8 | 85.7 | 73.7 | 60.7 | 65.2 | 65.6 | |
>3 g/day | 17.7 | 14.3 | 15.8 | 30.4 | 17.4 | 20.1 | |
Empiric regimen (%) | 0.64 | ||||||
Imipenem only | 19.5 | 7.1 | 18.4 | 21.4 | 8.7 | 18.0 | |
Imipenem + aminoglycoside | 37.2 | 50.0 | 42.2 | 48.2 | 34.8 | 41.0 | |
Amikacin | 24.8 | 28.6 | 21.1 | 41.1 | 26.1 | 28.3 | |
Tobramycin | 12.4 | 21.4 | 21.1 | 7.1 | 8.7 | 12.7 | |
Imipenem + glycopeptide | 15.0 | 21.4 | 21.1 | 8.9 | 21.7 | 15.6 | |
Vancomycin | 9.7 | 21.4 | 13.2 | 8.9 | 13.0 | 11.1 | |
Teicoplanin | 5.3 | - | 7.9 | - | 8.7 | 4.5 | |
Imipenem + aminoglycoside + glycopeptide | 28.3 | 21.4 | 18.4 | 21.4 | 34.8 | 25.4 |